NCT05579860View on ClinicalTrials.gov

A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

October 5, 2022

Primary Completion Date

May 22, 2023

Study Completion Date

May 22, 2023

Conditions
Healthy Participants
Interventions
DRUG

Olezarsen

Olezarsen will be administered by SC injection.

Trial Locations (1)

45227

Medpace Clinical Pharmacology Unit, Cincinnati

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY